The below online CPD modules from the current edition of Australian Pharmacist are available free for PSA members.
The article presents emerging injectable therapies for type 2 diabetes that are more effective or more convenient for users. They include longer-acting glucagon-like peptide analogues with better HbA1c lowering ability and a more user-friendly injection device, longer-acting once daily insulins, and a higher dose insulin glargine with a small injection volume.
Allergic rhinitis (commonly known as hay fever) affects approximately 18% of people in Australia and New Zealand. Hay fever can cause significant disruption to the lives of those affected, particularly those with moderate-to-severe symptoms. It can have a significant impact on learning and daily function and affect childhood behaviour and development. Yet it is commonly underdiagnosed, undertreated and sub-optimally self-managed. Pharmacists have a role in helping people effectively manage and treat hay fever and its symptoms.
Asthma is a common, chronic inflammatory disease of the airways that presents as episodes of wheezing, breathlessness, cough and chest tightness. It is due to widespread narrowing of the airways and obstruction of airflow. Among children aged 5–14 years, asthma is the leading cause of burden of disease in Australia.
In Australia this year, there are almost half a million people living with dementia. In older Australians (65 years and older), it is the single greatest cause of disability and the third leading cause of disability burden overall.4 In 2016, dementia was the second leading cause of death, surpassing heart disease.
PSA members can view articles and submit answers to assessment questions from Australian Pharmacist CPD from the previous 24 months by clicking the links below.